Literature DB >> 31096261

Stereotactic Radiosurgery for Pineal Region Tumors.

David Mathieu1, Christian Iorio-Morin2.   

Abstract

Pineal region tumors represent a heterogeneous group of different histologic entities, for which the management can be a significant challenge, due to their critical location and frequent aggressive behavior. Traditional management includes surgical resection, fractionated radiation therapy, and chemotherapy. Stereotactic radiosurgery (SRS) is being increasingly used in the treatment of these tumors. It is used as primary therapy for pineocytomas and papillary tumors of the pineal region, as an adjuvant radiation boost in combination with radiation or chemotherapy for pineoblastomas and germ cell tumors, or in the context of tumor recurrence. The reported morbidity is low, consisting in transient oculomotor disturbance in most cases. As a non-invasive alternative to microsurgical resection, SRS should always be considered when discussing these challenging cases.
© 2019 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2019        PMID: 31096261     DOI: 10.1159/000493062

Source DB:  PubMed          Journal:  Prog Neurol Surg        ISSN: 0079-6492


  3 in total

Review 1.  Multidisciplinary treatment of primary intracranial yolk sac tumor: A case report and literature review.

Authors:  Zhen-Ning Xu; Xiang-Yong Yue; Xiao-Ci Cao; Ya-Dong Liu; Bao-Shuan Fang; Wen-Hao Zhao; Chen Li; Shuai Xu; Ming Zhang
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

2.  Papillary tumor of the pineal region: Is stereotactic radiosurgery efficient for this rare entity?

Authors:  Hajar Bechri; Mohammed Yassaad Oudrhiri; Sidi Mamoun Louraoui; Adyl Melhaoui; Sanae Sefiani; Yasser Arkha; Abdessamad El Ouahabi
Journal:  Surg Neurol Int       Date:  2021-08-03

Review 3.  Pineal Gland Tumors: A Review.

Authors:  Gaia Favero; Francesca Bonomini; Rita Rezzani
Journal:  Cancers (Basel)       Date:  2021-03-27       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.